Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...

FDA Approved Drugs: Changes to Approved Drugs

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...

Drug Regulation

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...

Heart Failure Drugs: β-Blockers

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Can Deep Learning Blind Docking Methods be Used to Predict Allosteric Compounds?

Journal of chemical information and modeling·2025

Same author

The Effect of Femoral Head Size on Groin Pain in Total Hip Arthroplasty.

The Journal of arthroplasty·2022

Same author

ICD-10 Coding Mismatch in Computer and Robotic Assisted Primary Total Hip Arthroplasty.

The Journal of arthroplasty·2021

Same author

Using synthetic peptides and recombinant collagen to understand DDR-collagen interactions.

Biochimica et biophysica acta. Molecular cell research·2019

Same author

Management of an Unusual Periprosthetic Giant Cell Tumor of Bone of the Proximal Tibia.

Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews·2018

Same author

Children and Adults With Rare Diseases Need Innovative Medical Devices.

Journal of medical devices·2018

Same journal

Correction: A Hidden Indicator of Cardiovascular Health: Serum Gamma-Glutamyl Transferase in Focus.

Journal of cardiovascular translational research·2026

Same journal

ChemoCardioNet: An Explainable Multimodal Transformer for Early Prediction of Chemotherapy-Induced Cardiotoxicity.

Journal of cardiovascular translational research·2026

Same journal

Metabolic Heterogeneity Across Heart Failure Subtypes Defined by Integrative Multi-Omics Analysis.

Journal of cardiovascular translational research·2026

Same journal

The Immediate Impact of Infarct Size on the Systemic Inflammatory Response: IL-6 as Central Mediator Identified through Biomarker and Proteomic Profiling.

Journal of cardiovascular translational research·2026

Same journal

Extracellular Vesicles Link Cerebral Ischemia to Coronary Microvascular Dysfunction - Role for RGD Motif-Activated Endothelin Signaling.

Journal of cardiovascular translational research·2026

Same journal

Tracing the pathogenic PLN p.(Arg14del) variant across the globe; more than just a local curiosity.

Journal of cardiovascular translational research·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 12, 2026

In Vitro Thrombosis Test for Ventricular Assist Devices

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

FDA's perspectives on cardiovascular devices.

Eric A Chen¹, Sonna M Patel-Raman, Kathryn O'Callaghan

¹Center for Devices and Radiological Health, U.S. Food and Drug Administration, 9200 Corporate Boulevard, HFZ-450 Room 220V, Rockville, MD 20850, USA. eric.chen@fda.hhs.gov

Journal of Cardiovascular Translational Research

|June 19, 2010

Summary

This summary is machine-generated.

The FDA ensures medical device safety and effectiveness through rigorous preclinical and clinical data review. This article details the regulatory pathways for cardiovascular devices in U.S. clinical trials.

More Related Videos

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes

Published on: December 16, 2022

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Related Experiment Videos

Last Updated: Jun 12, 2026

In Vitro Thrombosis Test for Ventricular Assist Devices

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes

Published on: December 16, 2022

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Area of Science:

Medical Devices
Cardiovascular Technology
Regulatory Science

Background:

The U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) ensures medical device safety and effectiveness.
High-risk cardiovascular devices require extensive preclinical testing and human clinical trials for FDA approval.

Purpose of the Study:

To review the regulatory framework for cardiovascular device marketing applications.
To describe the process for obtaining approval for U.S. clinical trials of cardiovascular devices.

Main Methods:

Review of FDA regulations and guidelines for medical device approval.
Description of the clinical trial process for cardiovascular devices.

Main Results:

The FDA's approval process involves evaluating preclinical data and clinical trial outcomes.
Successful clinical trials demonstrate a device's predicted performance and favorable risk-benefit profile.

Conclusions:

Understanding the regulatory landscape is crucial for cardiovascular device development.
Navigating the U.S. clinical trial approval process is essential for market access.